Could a $0.50 heartburn pill ease sickle cell pain?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * child or adolescent aged 1 year to 17 years and 10 months, followed at the Necker-Enfants malades Hospital for a SS or Sβ0 SCD; * having at least one vaso-occlusive crisis in the year prior to inclusion; * for young girl of childbearing age (≥ 15 years old), a negative pregnancy test; * signed informed consent of the 2 parents or legal representative(s) and of the child of expressive age or the adolescent; * beneficiary of social security coverage or entitled (excluding AME) Exclusion Criteria: * treatment with crizanlizumab (anti-P-selectin antibody); * treatment with atazanavir/ritonavir in combination with tenofovir; * known hypersensitivity to famotidine or to other histamine type 2 (H2) receptor antagonists; * cardiovascular history such as: arrhythmia, AVB (atrioventricular block), QT prolongation; * renal failure characterized by creatinine clearance \<60 mL/min; * hepatic cytolysis (ALT ≥ 3N); * neutropenia (\<1 G/L), thrombocytopenia (\<80 G/L), reticulopenia (\<80 G/L); * predictable poor adherence to treatment; * pregnancy or breastfeeding; * participation in another interventional research involving the human person; * planned bone marrow transplant or gene therapy within one month of inclusion. Within 3 months prior to inclusion: * red blood cell transfusion; * introduction of hydroxyurea or modification of hydroxyurea doses; * introduction of L-glutamine or modification of L-glutamine doses; * introduction of voxelotor or modification of voxelotor doses; * taking oral or IV corticosteroids or any other immunomodulatory treatment; * taking an antihistamine treatment In the month preceding inclusion: * occurrence of a vaso-occlusive crisis, acute chest syndrome or any vaso-occlusive phenomenon (acute splenic sequestration, priapism, stroke, occlusion of the central retinal artery, papillary necrosis); * occurrence of fever (≥ 38°C) or any infectious episode, febrile or not, suspected or confirmed, of a viral, bacterial, fungal or parasitic nature ; * occurrence of an acute hemolytic episode (increase in jaundice and pallor, decrease in hemoglobin level of ≥ 1 g/dL compared to baseline hemoglobin, increase in LDH and/or AST and/or free bilirubin deemed significant by the child's referring physician).